AU2004217433A1 - Vectors used to create hybrid constant regions - Google Patents

Vectors used to create hybrid constant regions Download PDF

Info

Publication number
AU2004217433A1
AU2004217433A1 AU2004217433A AU2004217433A AU2004217433A1 AU 2004217433 A1 AU2004217433 A1 AU 2004217433A1 AU 2004217433 A AU2004217433 A AU 2004217433A AU 2004217433 A AU2004217433 A AU 2004217433A AU 2004217433 A1 AU2004217433 A1 AU 2004217433A1
Authority
AU
Australia
Prior art keywords
constant region
region
light chain
chain constant
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004217433A
Other languages
English (en)
Inventor
Katherine S. Bowdish
Shana Frederickson
Toshiaki Maruyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2004217433A1 publication Critical patent/AU2004217433A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2004217433A 2003-03-04 2004-03-04 Vectors used to create hybrid constant regions Abandoned AU2004217433A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45182003P 2003-03-04 2003-03-04
US60/451,820 2003-03-04
PCT/US2004/006571 WO2004078937A2 (en) 2003-03-04 2004-03-04 Vectors used to create hybrid constant regions

Publications (1)

Publication Number Publication Date
AU2004217433A1 true AU2004217433A1 (en) 2004-09-16

Family

ID=32962642

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004217433A Abandoned AU2004217433A1 (en) 2003-03-04 2004-03-04 Vectors used to create hybrid constant regions

Country Status (6)

Country Link
US (1) US20070009957A1 (cg-RX-API-DMAC7.html)
EP (1) EP1606387A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006520610A (cg-RX-API-DMAC7.html)
AU (1) AU2004217433A1 (cg-RX-API-DMAC7.html)
CA (1) CA2517519A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004078937A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2002246632B2 (en) 2000-12-08 2007-04-05 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
ES2255616T3 (es) 2001-04-27 2006-07-01 Alexion Pharmaceuticals, Inc. Vectores fagemidos.
EP2463305B1 (en) 2006-01-12 2016-05-11 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
CA2694121C (en) 2007-07-25 2016-06-07 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
US20110059471A1 (en) * 2008-03-14 2011-03-10 Medinet Co., Ltd. Antibody having an immune-enhancement function
PL2346994T3 (pl) 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
PL3248462T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
JP7627413B2 (ja) * 2020-08-21 2025-02-06 ファチアブジェン インコーポレイテッド ガンマ定常領域（Ｃγ１）とイプシロン定常領域（Ｃε２－４）とが融合された重鎖及び軽鎖の定常領域からなる抗体断片及びその用途
CN117430696A (zh) * 2022-07-22 2024-01-23 北京智仁美博生物科技有限公司 用于表达Fab片段库的重组系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US7119248B1 (en) * 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US6258529B1 (en) * 1994-12-01 2001-07-10 Oravax, Inc. PCR amplification of rearranged genomic variable regions of immunoglobulin genes
BR9708910A (pt) * 1996-05-04 1999-08-03 Zeneca Ltd Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
WO2002046477A2 (en) * 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
ES2255616T3 (es) * 2001-04-27 2006-07-01 Alexion Pharmaceuticals, Inc. Vectores fagemidos.
WO2003002608A1 (fr) * 2001-06-28 2003-01-09 Kyowa Hakko Kogyo Co., Ltd. Anticorps humanise contre le facteur-8 de croissance des fibroblastes et fragment de cet anticorps

Also Published As

Publication number Publication date
WO2004078937A3 (en) 2005-12-22
JP2006520610A (ja) 2006-09-14
CA2517519A1 (en) 2004-09-16
EP1606387A4 (en) 2008-04-23
WO2004078937A2 (en) 2004-09-16
EP1606387A2 (en) 2005-12-21
US20070009957A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
US20070009957A1 (en) Vectors used to create hybrid constant regions
AU2002360068B2 (en) Method for cloning of variable domain sequences
AU766253B2 (en) Modulation of polypeptide display on modified filamentous phage
EP0589877B2 (en) METHODS FOR PRODUCING FUNCTIONAL, SINGLE-CHAIN Fv ANTIBODY FRAGMENTS ON THE SURFACE OF BACTERIOPHAGE PARTICLES
USRE42130E1 (en) Phagemid vectors
CN102770555A (zh) 改善的细菌膜蛋白分泌
EP3440208B1 (en) Vectors for cloning and expression of proteins, methods and applications thereof
AU2003253193B2 (en) Novel tricistronic vectors and uses therefor
US11479879B2 (en) Triple vector for expressing antibody molecules in full therapeutic format
AU2010322202B2 (en) Display of disulfide linked dimeric proteins on filamentous phage
JP2012503983A (ja) 適合性ディスプレイベクター系
JP2012503982A (ja) 適合性ディスプレイベクター系
KR20220026869A (ko) 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
CA3038593C (en) Triple vector for expressing antibody molecules in full therapeutic format
US6440700B1 (en) Method of combinatorial protein synthesis based on ribosomal frameshifting
WO2003097796A2 (en) T7 bacteriophage display of fabs
WO2002046436A9 (en) Plasmid vectors
HK1060591A (en) A method for in vitro molecular evolution of protein function

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application